Oxygenta Pharmaceutical Ltd.
Snapshot View

23.05 -1.10 ▼-4.6%

24 May 2022, 04:01:00 PM
Volume: 603

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.ssorganics.co.in
Market Cap 32.81 Cr.
Enterprise Value(EV) 83.78 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) -0.43 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2022-03
Industry PE 28.41 Trailing Twelve Months Ending 2022-03
Book Value / Share -24.38 Trailing Twelve Months Ending 2022-03
Price to Book Value -0.95 Calculated using Price: 23.10
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 1.42 Cr. 14,201,300 Shares
FaceValue 10
Company Profile

SS Organics was incorporated in 1990, is a pharmaceutical company involved in the manufacture and marketing of bulk drugs and intermediates.

A wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs are manufactured. The product range also includes omeprazole, rabeprazole sodium, lansoprazole, esomeprazole magnesium trihydrate, non-pariel seeds, pantoprazole pellets, diclofenac sodium pellets, gabapentior, mooxafloxacin, ramipril, atorvastatin, and voriconazole.

Designed and built as per US FDA standards for production of bulk drugs and custom synthesis of intermediates, the plant located in the Medak district of Andhra Pradesh has an installed capacity 320 TPA. Major export destinations include Europe, USA, South America, and Asia Pacific Region. It reaches the America markets through its subsidiary based in Maryland, USA.

The registered office is at Survey No 252/1, Aroor Village, Sadasivapet Mandal, Medak, Andhra Pradesh.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-4.55%
1 Week
-6.68%
1 Month
-1.91%
3 Month
+5.01%
6 Month
-17.68%
1 Year
+215.75%
2 Year
+215.75%
5 Year
+75.29%
10 Year
+220.14%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%)
Return on Capital Employed (%) -80.52 -183.16
Return on Assets (%) -10.98 -24.53 -33.71 -29.05 -29.92 -25.13 -17.07 -29.10 11.16

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds -5 -9 -16 -22 -27 -32 -35 -41 -38 -35
Non Curr. Liab. 11 15 18 21 31 31 40 44 54 59
Curr. Liab. 11 12 16 21 16 18 17 16 18 7
Minority Int.
Equity & Liab. 17 18 18 20 19 17 21 19 34 31
Non Curr. Assets 15 17 13 14 13 13 12 12 18 22
Curr. Assets 1 2 5 5 6 4 9 7 16 9
Misc. Exp. not W/O
Total Assets 17 18 18 20 19 17 21 19 34 31

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 2 6 12 8 13 21 14 52 61
Other Income 0 0 1 1 0 0 0
Total Income 3 6 12 9 14 21 14 52 61
Total Expenditure -2 -6 -10 -17 -13 -17 -23 -22 -48 -59
PBIDT -2 -3 -4 -4 -4 -3 -2 -8 4 1
Interest 0 0 -1 -1 -1 -1 -1 -2 -1
Depreciation -1 -3 -1 -1 -1 -1 -1 -1 -2
Taxation 0 1 0 0 0 0 0 0
Exceptional Items 4 2 1
PAT -2 -4 -6 -6 -6 -5 -3 -6 3 -1
Adjusted EPS -2 -4 -6 -5 -6 -4 -3 -6 3 0

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 0 -1 -3 -4 1 1 1 -8 -3 -2
Cash Fr. Inv. -3 -2 1 -2 -1 0 -1 -1 -7
Cash Fr. Finan. 0 4 4 3 1 0 -1 8 3 9
Net Change 1 -1 0 0 0 0 0 0 0
Cash & Cash Eqvt 1 0 0 0 0 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 17.17 17.17 17.17 17.17 17.17 17.17 12.33 12.33 12.33
Public 82.83 82.83 82.83 82.83 82.83 82.83 87.67 87.67 87.67
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Sat, 21 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 33 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby enclose copies of newspaper clippings of the Audited Financial results of the Company for the Quarter and Year ended 31-03-2022 published on 21-05-2022 in Business Standard (all editions) and Nava Telangana (Hyderabad edition).The above information is also available on the website of the Company: http://oxygentapharma.com/This is for your kind information and records.
Sat, 21 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and SEBI Circular No CIR/CFD/CMD1/27/2019 dated 08-02-2019 We hereby submit the Annual Secretarial Compliance Report for the year ended 31st March 2022 issued by M/s. P S Rao & Associates Practicing Company Secretaries Hyderabad.
Fri, 20 May 2022
Board Meeting Outcome for Submission Of Audited Financial Results For The Quarter And Year Ended 31St March 2022
The Board at its meeting held today i.e. Friday 20th May 2021 transacted inter-alia the following businesses:

1. Financial Results:
The Board approved the Audited Financial Results for the fourth quarter and year ended 31st March 2022. In this regard please find the enclosed:

? Audited Financial Results of the Company for the quarter and year ended 31st March 2022

? Auditors report in respect of the Audited Financial Results of the Company for the fourth quarter and year ended 31st March 2022

? Declaration pursuant to Regulation 33(3)(d) of Listing Regulations in terms of the audit reports with unmodified opinion.

2. Appointment of Company Secretaries as Secretarial Auditors of the Company for the financial year 2022-23.

3. Appointment of Chartered Accountants as Internal Auditors of the Company for the financial year 2022-23.

The meeting of Board of Directors of the Company commenced at 03:00 P.M and concluded at _______ P.M.

Technical Scans View Details

Tue, 24 May 2022
Close Crossing Last Week Low Close Crossing Last Week Low
Close Crossing Last Month Close from Above Close Crossing Last Month Close from Above
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low
High Increase 1 Year High Increase 1 Year

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,371.20 914.30 -0.8%
Divi's Laboratories Ltd. 97,215.92 3,662.05 -6.0%
Cipla Ltd. 78,341.65 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. 72,413.55 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. 52,337.62 3,640.00 -2.2%
Gland Pharma Ltd. 47,375.00 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. 44,015.42 2,601.25 -0.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.04 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 32.84 3,662.05 -6.0%
Cipla Ltd. Consolidated 2022-03 31.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 33.18 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.18 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2022-03 39.10 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 36.11 2,601.25 -0.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 8.29 3,662.05 -6.0%
Cipla Ltd. Consolidated 2022-03 3.76 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.77 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.46 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2022-03 6.62 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 6.81 2,601.25 -0.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 0.10 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,601.25 -0.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 14.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,601.25 -0.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 14.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,601.25 -0.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 19,159.59 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,601.25 -0.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 2,401.30 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,601.25 -0.6%